

Federal Employee Program.

INBRIJA
PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services

Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Patient Information (required)				Provider Information (required)			
Date:				Provider Name:			
Patient Name:				Specialty:	NPI:	NPI:	
Date of Birth:		Sex: Male Female		Office Phone:	Office Fax:	Office Fax:	
Street Address:				Office Street Address:			
City:		State:	Zip:	City:	State:	Zip:	
Patient ID:]	Physician Signature:			
PHYSICIAN COMPLETES							
Inbrija (levodopa inhalation powder) *Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit NOTE: Form must be completed in its ontirety for processing							
NOTE : Form must be completed in its entirety for processing							
Is this request for brand or generic? ☐ Brand ☐ Generic							
How many cap	sules are needed ev	ery 90 days?	capsule	(s) per 90 days			
☐ Parkin	patient's diagnosis? son's disease experi diagnosis (please sp	encing off episode					
2. Does the pa	tient have asthma or	chronic obstructi	ve pulmonary d	isease (COPD)? □Yes □N	lo		
3. Will Inbrija	be used in combina	tion with carbidor	pa/levodopa?	Yes □No			
4. Has the pati	ent been on Inbrija	continuously for the	he last 4 month s	s, excluding samples? Please	select answer b	elow:	
□ NO – thi	s is INITIATION o	of therapy, please a	answer the follo	wing questions:			
	the patient had inade apy? □Yes □No	equate control of t	heir symptoms	on maximum tolerated doses of	of oral carbidopa	a/levodopa	
b. Has the patient been taking a MAOI (monamine oxidase inhibitor) within the past 14 days such as Nardil (phenelzine) or Parnate (tranylcypromine)? □Yes □No							

b. Will the patient be taking Inbrija in combination with a MAOI (monamine oxidase inhibitor) such as Nardil (phenelzine) or

□ YES – this is a PA renewal for CONTINUATION of therapy, please answer the following questions:

a. Has there been an improvement in symptoms? □Yes □No

Parnate (tranylcypromine)? □Yes □No



INBRIJA PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan **Prior Approval** P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 **Attn. Clinical Services** Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests securely online. Online submissions may receive instant responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to Caremark.com/ePA.
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. Please only fax the completed form once as duplicate submissions may delay processing times.

faster... Introducing ePA! Online Prior Authorizations in minutes through Caremark.com/ePA. Sign up today!

CVS/caremark

